Skip to main content
For Healthcare Professionals
Banner-Background

MOST COMMON AEs

JASCAYD® had a favorable tolerability and safety profile1

  • JASCAYD® treatment does not require liver or lab monitoring at treatment initiation2

ADVERSE EVENTS IN ≥10% OF JASCAYD® PATIENTS AND MORE OFTEN THAN PLACEBO1

 

Placebo +/- nintedanib (n=392)

JASCAYD® 18 mg +/- nintedanib (n=391)

Diarrhea

26%

37%

Cough

16%

17%

Weight decreased

8%

14%

Pneumonia

11%

13%

Nausea

7%

12%

Anxiety

11%

12%

ADVERSE EVENTS IN ≥10% OF JASCAYD® PATIENTS AND MORE OFTEN THAN PLACEBO1

 

Placebo +/- nintedanib (n=392)

JASCAYD® 9 mg +/- nintedanib (n=393)

Diarrhea

26%

33%

Cough

16%

14%

Weight decreased

8%

10%

Pneumonia

11%

11%

Nausea

7%

9%

Anxiety

11%

11%

Quicklinks

RISK OF INFECTION

JASCAYD® demonstrated a lower risk of upper respiratory tract infection compared to placebo1

OVERALL POPULATION1

 

Placebo (n=392)

JASCAYD® 18 mg (n=391)

Risk of upper respiratory tract infection

17%

14%

OVERALL POPULATION1

 

Placebo (n=392)

JASCAYD® 9 mg (n=393)

Risk of upper respiratory tract infection

17%

12%

FREQUENCY OF DIARRHEA

Frequency of diarrhea was dependent on the presence of background nintedanib2

The most frequent adverse event associated with JASCAYD® was diarrhea, and in most cases it was mild to moderate in intensity and generally occurred within the first 3 months2

PPF-Summary-Safety-18 mg

The most frequent adverse event associated with JASCAYD® was diarrhea, and in most cases it was mild to moderate in intensity and generally occurred within the first 3 months2

PPF-Summary-Safety-9mg

Only 1% of patients taking JASCAYD® without nintedanib discontinued treatment due to diarrhea events1

OTHER SAFETY AND TOLERABILITY CONSIDERATIONS

Safety and tolerability considerations when prescribing JASCAYD®2

Safety and tolerability considerations report
Diarrhea, nausea, and decreased appetite were frequently reported adverse reactions, particularly with concomitant use of nintedanib or pirfenidone.
Safety and tolerability considerations dose
Treatment may also be associated with dose-dependent weight loss, particularly with concomitant use of nintedanib.

Psychological disorders are common in PPF and IPF. While no imbalance was seen with JASCAYD® vs placebo in psychiatric events, routine monitoring is recommended2

Quicklinks
References

  1. Wijsenbeek MS, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Maher TM, Martinez FJ, Oldham JM, Richeldi L, Valenzuela C, Gu H, Ritter I, Stowasser S, Kreuter M. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial. Eur Respir J. Published online March 26, 2026.

  2. JASCAYD® UAE Local SmPC; May 2026.

  3. Wijsenbeek MS, Assassi S, Azuma A, et al. Effect of nerandomilast on clinical outcomes in patients with progressive pulmonary fibrosis (PPF): results from the final database lock of the FIBRONEER-ILD trial. 2025. Presented at: European Respiratory Society (ERS) International Congress; September 2025; Vienna, Austria. Poster available from: https://www.globalmedcomms.com/respiratory/ERS2025/Wijsenbeek1.

MLR ID: PC-AE-102895
Expiry Date: 10/05/2028